Company intelligence / Profile preview

Wepredic

Saint-Grégoire, Brittany, France

Ownership: Private
Development stage: Commercial

Overview

Wepredic provides advanced in vitro assay systems using proprietary human-derived cell lines such as HepaRG™, enabling predictive toxicology testing for drug safety assessment. Their platforms are widely used by pharmaceutical companies to model liver function and predict adverse effects without animal testing. They have established global partnerships to expand access to their technologies.

Therapeutic areas: GastroenterologyMetabolic DisordersOther
Modalities: Cell-based assay systemsRecombinant protein modelsSmall molecule probes
Industry: Drug Discovery Services

Partnerships

Dynamic42 GmbH (organ-on-chip technology partnership)ScitoVation (preferred CRO partner for Americas)

Beyond the preview

Go deeper on Wepredic.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wepredic.

Explore the full profile